NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market on Tuesday that its second quarter revenues rose 16 percent from Q2 2015, thanks in large part to a 12 percent increase in the number of Oncotype Dx tests delivered during the quarter.

For the three months ended June 30, the firm reported total revenues of $82.0 million, up from $70.6 million a year ago, and beating the consensus Wall Street estimate of $81.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.